by Paul Tracy, editor High-Yield International
Paris-based pharmaceutical giant Sanofi-Aventis (SNY) is in the midst of a transformation.
With the bulk of the major patent expirations now behind it, investors are beginning to focus on the firm's ability to deliver on growth drivers in the form of new blockbuster drugs.
Market News and Data brought to you by Benzinga APIsParis-based pharmaceutical giant Sanofi-Aventis (SNY) is in the midst of a transformation.
With the bulk of the major patent expirations now behind it, investors are beginning to focus on the firm's ability to deliver on growth drivers in the form of new blockbuster drugs.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Health CarePharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in